Los Angeles, USA, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Multiple System Atrophy Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
Multiple System Atrophy Clinical Trial Analysis and Therapeutic Assessment of 20+ Companies and MSA Drugs
DelveInsight’s “Multiple System Atrophy (MSA) Pipeline Analysis, 2020” highlights the details of the Multiple System Atrophy Pipeline Landscape Scenario, including disease overview, unmet needs, and Multiple System Atrophy therapeutic assessment of the key Multiple System Atrophy pipeline therapies.
Some of the key features of the Multiple System Atrophy Pipeline Report
Multiple System Atrophy is a rare, degenerative neurological disorder affecting the body's involuntary (autonomic) functions, including blood pressure, breathing, bladder function, and motor control. The Multiple System Atrophy cause is unknown. The vast majority of cases are sporadic.
Request Multiple System Atrophy Therapeutics Pipeline Assessment Sample Report
Prominent companies participating in the Multiple System Atrophy therapeutic development are covered in the pipeline report.
Multiple System Atrophy Pipeline Therapeutics
Verdiperstat is a potential first-in-class, oral, brain-penetrant, irreversible inhibitor of MPO that Biohaven Pharmaceutical Holding Company is developing for Multiple System Atrophy treatment. Verdiperstat also has the potential to be developed in a number of other disease indications associated with oxidative stress, inflammation, and neurodegeneration. Verdiperstat has also been known as BHV-3241 at Biohaven. The drug is currently in the phase III stage of development.
To know more about Multiple System Atrophy Drugs, request @ Multiple System Atrophy Therapeutics Pipeline Assessment Sample Report
Scope of Multiple System Atrophy Pipeline Therapeutics Report
Key Questions regarding Current Multiple System Atrophy Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
Multiple System Atrophy Pipeline Insight Table of Contents
1 | Report Introduction |
2 | Multiple System Atrophy Executive Summary |
3 | Multiple System Atrophy Overview |
4 | Multiple System Atrophy - DelveInsight's Analytical Perspective |
5 | Multiple System Atrophy Pipeline Therapeutics |
6 | Multiple System Atrophy Late Stage Products (Phase III) |
6.1 | Verdiperstat - Biohaven Pharmaceutical Holding Company |
7 | Multiple System Atrophy Mid Stage Products (Phase-II) |
7.1 | ATH 434: Alterity Therapeutics |
8 | Multiple System Atrophy Early Stage Products (Phase-I) |
8.1 | Affitope PD03: AFFiRiS |
9 | Multiple System Atrophy Pre-clinical Stage Products |
9.1 | ATH 434: Alterity Therapeutics |
10 | Multiple System Atrophy Therapeutics Assessment |
11 | Multiple System Atrophy Inactive Products |
12 | Company-University Collaborations (Licensing/Partnering) Analysis |
13 | Multiple System Atrophy Key Companies |
14 | Multiple System Atrophy Key Products |
15 | Multiple System Atrophy Unmet Needs |
16 | Multiple System Atrophy Market Drivers and Barriers |
17 | Multiple System Atrophy- Future Perspectives and Conclusion |
18 | Multiple System Atrophy Analyst Views |
19 | Appendix |
Browse Detailed TOC, Emerging Drugs and Key Companies @ Multiple System Atrophy Pipeline Scenario
Related Reports
DelveInsight’s Multiple System Atrophy (MSA) Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.
DelveInsight's Multiple System Atrophy (MSA) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Multiple System Atrophy (MSA) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight's Postmenopausal Vaginal Atrophy - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
Postmenopausal Vaginal Atrophy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Postmenopausal Vaginal Atrophy market.
DelveInsight's Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.
DelveInsight's Septic Shock Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.
DelveInsight's Geographic Atrophy (GA) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.